NASDAQ:NVCN - Neovasc Stock Price, Forecast & News

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Neovasc's stock reverse split on Friday, September 21st 2018. The 1-100 reverse split was announced on Tuesday, September 11th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 20th 2018. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 1 shares after the split.

Neovasc Inc (NASDAQ:NVCN) posted its quarterly earnings data on Tuesday, March, 29th. The medical equipment provider reported ($1,100.00) EPS for the quarter, beating analysts' consensus estimates of ($1,500.00) by $400.00. The medical equipment provider had revenue of $2.24 million for the quarter, compared to analysts' expectations of $3.26 million. View Neovasc's Earnings History.

Neovasc is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Neovasc.

1 brokerages have issued 12 month price objectives for Neovasc's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Neovasc's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 195.1% from the stock's current price. View Analyst Price Targets for Neovasc.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neovasc.

News articles about NVCN stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neovasc earned a news sentiment score of -3.5 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Neovasc.

Neovasc saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 304,400 shares, an increase of 106.1% from the January 15th total of 147,700 shares. Based on an average daily volume of 568,700 shares, the short-interest ratio is presently 0.5 days. Currently, 3.2% of the company's stock are sold short. View Neovasc's Current Options Chain.

Some companies that are related to Neovasc include PAVmed (PAVM), SANUWAVE Health (SNWV), BeyondAirInc . (XAIR), Pro-Dex (PDEX), Sensus Healthcare (SRTS), Nephros (NEPH), AIT Therapeutics (AITB), Nephros (NEPHD), Co-Diagnostics (CODX), Neuronetics (STIM), Apollo Endosurgery (APEN), Motus GI (MOTS), STRATA Skin Sciences (SSKN), T2 Biosystems (TTOO) and Delcath Systems (DCTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Rexahn Pharmaceuticals (REXN), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP) and Immune Pharmaceuticals (IMNP).

Neovasc's stock is owned by many different of retail and institutional investors. Top institutional investors include Magnetar Financial LLC (5.61%), Capital World Investors (3.55%), Virtu Financial LLC (0.13%) and Kessler Investment Group LLC (0.10%).

NVCN stock was acquired by a variety of institutional investors in the last quarter, including Magnetar Financial LLC, Capital World Investors, Virtu Financial LLC and Kessler Investment Group LLC.

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVCN stock can currently be purchased for approximately $3.05.

Neovasc has a market capitalization of $30.16 million and generates $1.75 million in revenue each year. The medical equipment provider earns $-108,040,000.00 in net income (profit) each year or ($27.30) on an earnings per share basis. Neovasc employs 98 workers across the globe.View Additional Information About Neovasc.

The official website for Neovasc is http://www.neovasc.com/.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V2J7. The medical equipment provider can be reached via phone at 604-248-4138 or via email at [email protected]